Table 5.

General Side Effects for AAPs

Side effect	Guideline(s)
Weight gain	APA (Andersen et al., 2005), TMAP, RANZCP
Other metabolic complications/metabolic syndrome	RANZCP
Glucose dysregulation/diabetes mellitus	APA
Dyslipidaemia	Hypertriglyceridemia (APA), hypercholesterolemia and hyperglycemia (particularly for olanzapine; TMAP)
Hyperprolactinemia	APA, MPG
QTc prolongation	APA, BAP (Haddad and Anderson, 2002; Leucht et al., 2013), MPG
Coronary heart disease/risk of sudden cardiac death	MPG (Ray et al., 2001; Hennessy et al., 2002; Reilly et al., 2002; Straus et al., 2004; Liperoti et al., 2005; Osborn et al., 2007; Stroup et al., 2009; Murray-Thomas et al., 2013)
Extrapyramidal side effects (including tardive dyskinesia and neuroleptic malignant syndrome)a	NICE, MPG (Baldessarini et al., 1988; Peluso et al., 2012), RANZCP, APA, TMAP
Acute kidney injury	MPG
Sedation	MPG
Postural hypotension	MPG
Anticholinergic effects	MPG
Hyponatraemia	MPG (Littrell et al., 1997; Kawai et al., 2002; Montgomery and Tekell, 2003; Meulendijks et al., 2010)
Sexual dysfunction	MPG
Increased risk of pneumonia	MPG
Increased risk of thromboembolism	MPG (Zhang et al., 2011; Barbui et al., 2014)

Abbreviations: APA, American Psychiatric Association; BAP, British Association of Psychopharmacology; CANMAT, Canadian Network for Mood and Anxiety Disorders; CPG-S, Clinical Practice Guidelines in the Spanish NHS; ICSI, Institute for Clinical Systems Improvement; NICE, National Institute for Health and Care Excellence; QTc, corrected QT interval; RANZCP, Royal Australian and New Zealand College of Psychiatrists; MPG, Maudsley Prescribing Guidelines; TMAP; Texas Medication Algorithm Project; WFSBP, World Federation of Societies of Biological Psychiatry.

^aSee individual guidelines for specific symptoms.